DaVita (NYSE:DVA) Reports Financial Improvements For 2024 But Stock Dips 12%

DaVita Inc. (NYSE:DVA) has reported substantial financial improvements for the full year 2024, including increased revenues and net income, along with continued share repurchases. Despite these positive earnings indicators, DaVita's stock price decreased by 12% over the last quarter. During this period, the company's extensive share buyback activity, which included the repurchase of over 3.1 million shares, was intended to bolster shareholder value. However, it seems that broader market influences overshadowed these efforts. The overall market experienced declines, as seen with the Dow Jones and major indexes posting weekly losses. Negative sentiment around health insurers, following news of investigations into UnitedHealth, could have indirectly weighed on DaVita shares. Additionally, while the market is up significantly over the past year, recent flat performance may have further muted gains. Overall, external market conditions likely influenced DaVita's quarterly stock performance more than company-specific achievements.

See the full analysis report here for a deeper understanding of DaVita.

Over the last five years, DaVita Inc. has provided a total shareholder return of 84.17%. This impressive performance includes the company's strategic efforts like significant share buybacks, which have bolstered stock value. Recent annual earnings announced in February 2025 highlighted impressive growth, with revenue reaching US$12.82 billion and net income rising significantly, reflecting improved financial health. While these figures indicate strong company performance, DaVita's stock return over the past year underperformed compared to the broader US market, which posted a 23.7% gain.

Despite facing challenges in the short term, such as broader market declines and negative sentiment around the healthcare sector, DaVita's relative value has remained attractive. Its Price-To-Earnings Ratio is notably below both the US Healthcare industry average and its peer group, showcasing its potential value acknowledgment by the market. Additionally, initiatives like the joint venture with Medtronic to advance kidney health technology signal DaVita's commitment to future growth, enhancing its appeal for long-term investors.

• Learn how DaVita's intrinsic value compares to its market price with our detailed valuation report.
• Assess the potential risks impacting DaVita's growth trajectory—explore our risk evaluation report.
• Already own DaVita? Link your portfolio to Simply Wall St and get alerts on any new warning signs to your stocks.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com